These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17596432)

  • 1. Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
    García-Piñeres A; Hildesheim A; Dodd L; Kemp TJ; Williams M; Harro C; Lowy DR; Schiller JT; Pinto LA
    Clin Vaccine Immunol; 2007 Aug; 14(8):984-9. PubMed ID: 17596432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.
    Pinto LA; Castle PE; Roden RB; Harro CD; Lowy DR; Schiller JT; Wallace D; Williams M; Kopp W; Frazer IH; Berzofsky JA; Hildesheim A
    Vaccine; 2005 May; 23(27):3555-64. PubMed ID: 15855014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
    Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients.
    García-Piñeres AJ; Hildesheim A; Dodd L; Kemp TJ; Yang J; Fullmer B; Harro C; Lowy DR; Lempicki RA; Pinto LA
    J Immunol; 2009 Feb; 182(3):1706-29. PubMed ID: 19155521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
    Thönes N; Müller M
    Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
    J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.
    Jagu S; Kwak K; Garcea RL; Roden RB
    Vaccine; 2010 Jun; 28(28):4478-86. PubMed ID: 20434552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.
    Emeny RT; Wheeler CM; Jansen KU; Hunt WC; Fu TM; Smith JF; MacMullen S; Esser MT; Paliard X
    J Virol; 2002 Aug; 76(15):7832-42. PubMed ID: 12097595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.
    Fraillery D; Zosso N; Nardelli-Haefliger D
    Vaccine; 2009 Apr; 27(17):2326-34. PubMed ID: 19428847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
    Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
    Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.
    Yan X; Wang D; Liang F; Fu L; Guo C
    Hum Vaccin Immunother; 2014; 10(12):3491-8. PubMed ID: 25483698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
    Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques.
    Nieto K; Stahl-Hennig C; Leuchs B; Müller M; Gissmann L; Kleinschmidt JA
    Hum Gene Ther; 2012 Jul; 23(7):733-41. PubMed ID: 22401308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation.
    de Witte L; Zoughlami Y; Aengeneyndt B; David G; van Kooyk Y; Gissmann L; Geijtenbeek TB
    Immunobiology; 2007; 212(9-10):679-91. PubMed ID: 18086370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Viscidi R; Harro CD; Kemp TJ; García-Piñeres AJ; Trivett M; Demuth F; Lowy DR; Schiller JT; Berzofsky JA; Hildesheim A
    Virology; 2006 Sep; 353(2):451-62. PubMed ID: 16863657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.